INCYTE CORP

Key metrics

Financial performance

Over the last 9 fiscal years INCYTE CORP's revenue grew from $1.11B to $5.14B, a compound annual growth rate of 18.6%. Net profit margin expanded from 9.4% to 25.0% over the same period - every figure below comes from the company's audited annual filings.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (2,536 filings)

Recent press releases

• Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference2026-05-26

  Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

• Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery2026-05-20

  Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery

• Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development2026-05-19

  Incyte (Nasdaq:INCY) and Edison Scientific today announced a strategic collaboration to employ Kosmos, Edison’s AI scientist, for Incyte’s discovery and development work.

• Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress2026-05-12

  Data from pivotal Phase 3 frontMIND trial evaluating tafasitamab (Monjuvi ® /Minjuvi ® ) in first-line diffuse large b-cell lymphoma (DLBCL) selected for prestigious Plenary Abstracts Session

• Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis2026-05-07

  First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) at the 2026 EADV Symposium

Similar companies

The largest companies sharing INCYTE CORP's SEC industry classification (services-commercial physical & biological research).